Hengyu Li

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 4

Top Topics

Long Non Coding Rna

Cell Proliferation

Top Venues

Cell death & disease

Journal of ovarian research

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Tao Han, Tingsong Chen, Lujun Chen, Kerui Li, Daimin Xiang, Yubei Gu, Hengyu Li, Yubei Gu
HLF promotes ovarian cancer progression and chemoresistance via regulating Hippo signaling pathway. Cell death & disease 14 (9) (2023)
Jieqiong Liu, Ying Wang, Zhenluan Tian, Ying Lin, Hengyu Li, Zhaowen Zhu, Qiang Liu, Shicheng Su, Yinduo Zeng, Weijuan Jia, Yaping Yang, Shengqiang Xu, He-Rui Yao, Wen Jiang, Erwei Song
Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer. Nature communications 13 (1) (2022)
Tao Han, Hao Zheng, Jin Zhang, Pinghua Yang, Hengyu Li, Zhangjun Cheng, Daimin Xiang, Ruoyu Wang
Downregulation of MUC15 by miR-183-5p.1 promotes liver tumor-initiating cells properties and tumorigenesis via regulating c-MET/PI3K/AKT/SOX2 axis. Cell death & disease 13 (3) (2022)
Wenman Zhao, Tao Han, Bao Li, Qianyun Ma, Pinghua Yang, Hengyu Li
miR-552 promotes ovarian cancer progression by regulating PTEN pathway. Journal of ovarian research 12 (1) (2019)